Achmea Investment Management B.V. lowered its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 13.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,817 shares of the conglomerate’s stock after selling 5,294 shares during the period. Achmea Investment Management B.V.’s holdings in Danaher were worth $7,763,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. FMR LLC lifted its holdings in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Danaher in the fourth quarter worth about $391,172,000. Van ECK Associates Corp boosted its position in shares of Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after acquiring an additional 916,513 shares during the period. Proficio Capital Partners LLC boosted its position in shares of Danaher by 29,287.7% in the fourth quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after acquiring an additional 586,925 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Insider Activity at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Stock Report on Danaher
Danaher Stock Performance
NYSE DHR opened at $203.96 on Friday. The firm has a market cap of $145.77 billion, a price-to-earnings ratio of 38.63, a PEG ratio of 2.66 and a beta of 0.82. The company has a 50-day simple moving average of $220.55 and a two-hundred day simple moving average of $241.22. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business posted $2.09 EPS. On average, equities analysts forecast that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher’s payout ratio is presently 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- What is the Australian Securities Exchange (ASX)
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What Are the FAANG Stocks and Are They Good Investments?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.